Cited by 312Genetic Neurodegenerative DiseasesCoenzyme Q10 studies and effectsNeurological diseases and metabolism

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

The Huntington Study Group·2001·Neurology

Open this paper in CoChat — free account

Abstract

OBJECTIVES: To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD). METHODS: The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events. RESULTS: Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10. CONCLUSIONS: Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.

Integrity signals

Registry

Crossref · 10.1212/wnl.57.3.397

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unified Huntington's disease rating scale: Reliability and consistency
Kremer, H. P. H. (1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,155
The hopkins verbal learning test: Development of a new memory test with six equivalent forms
Brandt, J. (1991) · Clinical Neuropsychologist · doi:10.1080/13854049108403297 · Cited by 1,317
Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Self-citation
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals
Penney, J. B., Young, A. B., Shoulson, I., Starosta‐Rubinstein, S., Snodgrass, S. R., Sanchez‐Ramos, J., Ramos‐Arroyo, M. A., Gomez, F., Penchaszadeh, G. K., Alvir, J., et al. (1990) · Movement Disorders · doi:10.1002/mds.870050202 · Cited by 218
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152

Flagged first, then by citations

Show all 19 references

Research works printed but not linked: 1

Reitan RM Wolfson D. The Halstead–Reitan Neuropsychological Test Battery. Tuscon: Neuropsychology Press 1958.

Sorted by citations

Items 201–300 of 311

Huntington's disease
Bonelli, R. M., & Beal, M. F. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00030-9 · Cited by 16
Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model
Hübener‐Schmid, J., Casadei, N., Teismann, P., Seeliger, M. W., Björkqvist, M., von Hörsten, S., Rieß, O., & Nguyen, H. P. (2012) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.04.009 · Cited by 16
Development of novel therapies for Huntington's disease: hope and challenge1
Qin, Z., Wang, J., & Gu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00520.x · Cited by 16
Important but not Enough – Information about HD Related Topics and Peer and Professional Support for Young Adults from HD Families
Braisch, U., Martínez‐Horta, S., MacDonald, M. E., & Orth, M. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160218 · Cited by 15
Simultaneous determination of ubiquinol and ubiquinone in skeletal muscle of pediatric patients
Pastore, A., Giovamberardino, G. D., Bertini, E., Tozzi, G., Gaeta, L. M., Federici, G., & Piemonte, F. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.02.018 · Cited by 15
Beneficial antioxidant effects of Coenzyme Q10 on reproduction
Carneiro, M. F. H., & Colaiácovo, M. P. (2022) · Vitamins and hormones · doi:10.1016/bs.vh.2022.10.004 · Cited by 16
Design optimization for clinical trials in early‐stage manifest Huntington's disease
Frost, C. D., Mulick, A. R., Scahill, R. I., Owen, G. N., Aylward, E., Leavitt, B. R., Dürr, A., Roos, R. A. C., Borowsky, B., Stout, J. C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27122 · Cited by 14
Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders
Rubinsztein, D. C. (2003) · Elsevier eBooks · doi:10.1016/b978-012566652-7/50035-6 · Cited by 14
Cardioprotective role of the coenzyme Q10 and coconut oil in acute aluminum phosphide poisoning: a randomized controlled clinical trial
Elsharkawy, R. E., Ghonem, M. M., El‐Sarnagawy, G. N., Nagy, A. A., & Heshmat, M. (2023) · Toxicology Research · doi:10.1093/toxres/tfad037 · Cited by 13
Morbus Huntington
Rollnik, J. D. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-4306-9 · Cited by 13
Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease
Lopes‐Ramos, C. M., Pereira, T. C., Dogini, D. B., Gilioli, R., & Lopes‐Cendes, Í. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165805 · Cited by 13
Geriatric Chorea
Lorincz, M. T. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2006.06.005 · Cited by 13
Hprt (CAG)146 mice: Age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
Tallaksen‐Greene, S. J., Ordway, J. M., Crouse, A. B., Jackson, W. S., Detloff, P. J., & Albin, R. L. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10855 · Cited by 13
Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies
Ross, C. A., Kronenbuerger, M., Duan, W., & Margolis, R. L. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00002-x · Cited by 14
Agreement between clinician-rated versus patient-reported outcomes in Huntington disease
Carlozzi, N. E., Boileau, N. R., Perlmutter, J. S., Chou, K. L., Stout, J. C., Paulsen, J. S., McCormack, M. K., Cella, D. F., NANCE, M. A., Lai, J., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8852-5 · Cited by 12
Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales
Sun, W., Zhou, D., Warner, J. H., Langbehn, D. R., Hochhaus, G., & Wang, Y. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1598 · Cited by 12
A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington’s Disease
Wipf, P., Polyzos, A. A., & McMurray, C. T. (2021) · Journal of Huntington s Disease · doi:10.3233/jhd-210510 · Cited by 12
Therapeutic Strategies for Huntington’s Disease
Mrzljak, L., & Muñoz-Sanjuán, I. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_250 · Cited by 12
Huntington Disease
Wagner, L. A., Menalled, L., Goumeniouk, A. D., Brunner, D., & Leavitt, B. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00018-7 · Cited by 12
Huntington's disease: The mystery unfolds?
Petersén, Å., & Brundin, P. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53012-9 · Cited by 12
Mitochondrial Markers in Aging and Primary Open-Angle Glaucoma
Liu, H., Mercieca, K., & Prokosch, V. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001448 · Cited by 10
Monitoring the Motor Phenotype in Huntington’s Disease by Analysis of Keyboard Typing During Real Life Computer Use
Lang, C., Gries, C., Lindenberg, K. S., Lewerenz, J., Uhl, S., Olsson, C., Samzelius, J., & Landwehrmeyer, G. B. (2021) · Journal of Huntington s Disease · doi:10.3233/jhd-200451 · Cited by 12
PET imaging of the basal ganglia
Laihinen, A., & Halsband, U. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2006.03.004 · Cited by 11
Lipidomics of Huntington’s Disease: A Comprehensive Review of Current Status and Future Directions
Yılmaz, A., Akyol, S., Ashrafi, N., Saiyed, N., Türkoğlu, O., & Graham, S. F. (2025) · Metabolites · doi:10.3390/metabo15010010 · Cited by 10
Pharmacological approaches to disease-modifying therapies in Parkinson’s disease
O’Neill, M. J., & Siemers, E. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.6.819 · Cited by 10
Huntington’s disease: A decade beyond gene discovery
Hogarth, P. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0003-3 · Cited by 10
Mitochondria in neurodegeneration
Beal, M. F. (2002) · Springer eBooks · doi:10.1007/978-2-8178-0929-8_3 · Cited by 10
Oral Repeated-Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs
Yerramilli-Rao, P., Beal, M. F., Watanabe, D., Kieburtz, K. D., de Blieck, E. A., Kitano, M., Hosoe, K., Funahashi, I., & Cudkowicz, M. (2012) · International Journal of Toxicology · doi:10.1177/1091581811425256 · Cited by 9
Update on huntington’s disease
Berman, S. B., & Greenamyre, J. T. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0019-6 · Cited by 9
Neuroprotective potential of coenzyme Q10
Tripathi, S., Mishra, R., & Singh, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00057-9 · Cited by 9
Huntington’s disease
Higgins, D. S. (2006) · Current Treatment Options in Neurology · doi:10.1007/s11940-006-0014-x · Cited by 8
Tetrabenazine in Huntington's Disease Chorea
Chitnis, S., & Karunapuzha, C. A. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2134 · Cited by 8
Treatment and management issues in ataxic diseases
Perlman, S. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00046-2 · Cited by 8
Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts
Lubansu, A., Abeloos, L., Bockstael, O., Lehtonen, E., Blum, D. L., Brotchi, J., Levivier, M., & Tenenbaum, L. (2007) · Cell Transplantation · doi:10.3727/000000007783472372 · Cited by 8
Novel Gene Therapeutic Strategies for Neurodegenerative Diseases
Maguire‐Zeiss, K. A., & Federoff, H. J. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_9 · Cited by 8
Evidence-Based Review on Symptomatic Management of Huntington’s Disease
Shin, J. H., Yang, H.-J., Ahn, J. H., Jo, S., Chung, S. J., Lee, J., Kim, H. S., Kim, M., & on behalf of the Korean Huntington’s Disease Society (2024) · Journal of Movement Disorders · doi:10.14802/jmd.24140 · Cited by 7
Nutrition and Huntington’s Disease– A Review of Current Practice and Theory
Gaba, A. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00610-x · Cited by 8
Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients
Kuriyama, N., Nakamura, T., Nakazawa, H., Wen, T., Berra, L. M., Bittner, E. A., Goverman, J. M., & Kaneki, M. (2022) · Metabolites · doi:10.3390/metabo12070613 · Cited by 7
Inherited movement disorders
Sharma, N., & Standaert, D. G. (2002) · Neurologic Clinics · doi:10.1016/s0733-8619(01)00014-7 · Cited by 7
A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease
Yu, M., & Bega, D. (2019) · Europe PMC (PubMed Central) · doi:10.7916/d8-z9yh-1n90 · Cited by 6
Navigating the uncommon: challenges in applying evidence-based medicine to rare diseases and the prospects of artificial intelligence solutions
Rennie, O. (2024) · Medicine Health Care and Philosophy · doi:10.1007/s11019-024-10206-x · Cited by 7
Coenzyme Q10: Role in Less Common Age-Related Disorders
Mantle, D., & Hargreaves, I. P. (2022) · Antioxidants · doi:10.3390/antiox11112293 · Cited by 6
Huntington's Disease
Biglan, K. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-03432-6.50067-2 · Cited by 6
Therapeutic strategies for Huntington’s disease: current approaches and future direction
Gulzar, M., Kauser, S., Khan, S., Adnan, M., & Hassan, M. I. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2552593 · Cited by 5
Therapeutic Strategies in Neurodegenerative Diseases
Anderson, K. M., & Mosley, R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_42 · Cited by 5
The most appropriate primary outcomes to design clinical trials on H untington's disease: meta‐analyses of cohort studies and randomized placebo‐controlled trials
Salem, L., Saleh, N., Youssov, K., Olivier, A., Charles, P., Scherer‐Gagou, C., Verny, C., Bachoud‐Lévi, A., & Maison, P. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12077 · Cited by 5
Of rodents and men: understanding the emergence of motor and cognitive symptoms in Huntington disease
Abada, Y.-S. K., & Ellenbroek, B. A. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000217 · Cited by 5
Huntington Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50018-8 · Cited by 5
Clinical and Research Advances in Huntington's Disease
SuttonBrown, M., & Suchowersky, O. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100003231 · Cited by 5
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment
Greenlee, H., Crew, K. D., Maurer, M., Kalinsky, K. M., Cremers, S., Naini, A., Tsai, W. Y., Shi, Z., Brogan, F., & Hershman, D. L. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251388014 · Cited by 4
Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An in-depth review
Forouzanfar, F., Ahmadzadeh, A. M., Pourbagher‐Shahri, A. M., & Gorji, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177690 · Cited by 4
Therapeutic Strategies in Huntington's Disease
Kanazawa, I. (2006) · Journal of Clinical Neurology · doi:10.3988/jcn.2006.2.4.213 · Cited by 4
Dietary Supplements: Current Knowledge and Future Frontiers
Costello, R. B., Leser, M., & Coates, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-385-5_28 · Cited by 4
Therapeutic strategies in Huntington?s disease
Alberch, J., Canals, J. M., & Pérez‐Navarro, E. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.449 · Cited by 4
A pilot assessment of parental practices and attitudes regarding risk disclosure and clinical research involving children in Huntington disease families
Dure, L. S., Quaid, K. A., & Beasley, T. M. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31818adb01 · Cited by 4
Bewegungsstörungen
Ceballos-Baumann, A., Schwarz, M., Wessel, K., & Meyring, S. (2006) · Springer eBooks · doi:10.1007/3-540-31176-9_39 · Cited by 4
Spinocerebellar degeneration
Perlman, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1637 · Cited by 4
Translating therapies for Huntington’s disease from genetic animal models to clinical trials
Hersch, S. M., & Ferrante, R. J. (2004) · Neurotherapeutics · doi:10.1007/bf03206614 · Cited by 4
Ferroptosis-related stress during aging and its relevance to disease
Maher, P. A., Soriano‐Castell, D., Dar, N. J., Soriano, S., & Currais, A. J. M. (2025) · GeroScience · doi:10.1007/s11357-025-01929-7 · Cited by 6
Transplants of CNTF-producing Cells for the Treatment of Huntington's Disease
Escartin, C., Hantraye, P., & Déglon, N. (2007) · Elsevier eBooks · doi:10.1016/b978-012369415-7/50023-5 · Cited by 3
Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington’s Disease
McGarry, A. J., for the Huntington Study Group 2CARE Investigators and Coordinators, McDermott, M., Kieburtz, K. D., Peng, J. L., & Cudkowicz, M. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-190391 · Cited by 3
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease
McGarry, A. J., Auinger, P., Kieburtz, K. D., Bredlau, A., Hersch, S. M., & Rosas, H. D. (2022) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001161 · Cited by 3
Classification and Clinical Features of Movement Disorders
Jurkowski, A. J., & Stacy, M. A. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50002-5 · Cited by 3
Oxidative Stress Reduction (Prong-3)
DePace, N. L., & Colombo, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-17016-5_5 · Cited by 3
Huntington's Disease-like 2
Margolis, R. L., Holmes, S. E., Rudnicki, D. D., O’Hearn, E., Ross, C. A., Pletniková, O., & Troncoso, J. C. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50017-x · Cited by 3
Analysis of Participant Withdrawal in Huntington Disease Clinical Trials
Banno, H., Andrzejewski, K. L., McDermott, M., Murphy, A., Majumder, M., de Blieck, E. A., Auinger, P., Cudkowicz, M., & Atassi, N. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170246 · Cited by 2
AI-Enhanced Transcriptomic Discovery of Druggable Targets and Repurposed Therapies for Huntington’s Disease
Araldi, R. P., Pinto, J. R. D., & Kerkis, I. (2025) · Brain Sciences · doi:10.3390/brainsci15080865 · Cited by 2
REV1 inhibition enhances trinucleotide repeat mutagenesis
Siegel, A., Almstead, D., Kothandaraman, N., Reich, J., Lamkin, E. N., Victor, J., Grover, A., Ikeh, K., Koval, H., Crompton, A., et al. (2025) · Open Biology · doi:10.1098/rsob.250234 · Cited by 2
Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.006 · Cited by 2
Managing Chorea in Huntington’s Disease
Vaou, O., & Frank, S. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.40 · Cited by 2
Huntington disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00014-7 · Cited by 2
Mechanistic Insights into the Polyglutamine Ataxias
Miller, V. M., & Paulson, H. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-36534-3_23 · Cited by 2
Treatment of Mitochondrial Diseases
DiMauro, S. (2002) · Springer eBooks · doi:10.1007/978-2-8178-0929-8_26 · Cited by 2
Clinical Features and Care
Shoulson, I. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00025-8 · Cited by 2
Coenzyme Q10 (Ubiquinone, Ubidecarenone)
Cupp, M. J., & Tracy, T. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-303-3_5 · Cited by 2
Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit
Frank, W., Lindenberg, K. S., Mühlbäck, A., Lewerenz, J., & Landwehrmeyer, G. B. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01224-8 · Cited by 4
Taxonomy and Clinical Features of Movement Disorders
Hickey, P., & Stacy, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00001-9 · Cited by 1
Huntington disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00013-5 · Cited by 1
Huntington Disease and Other Choreas
Videnović, A., & Shannon, K. M. (2012) · Humana Press eBooks · doi:10.1007/978-1-60327-120-2_2 · Cited by 2
Dentatorubral-pallidoluysian atrophy (DRPLA): model for Huntington's disease and other polyglutamine diseases
Ross, C. A., Ellerby, L., Wood, J., & Nucifora, F. C. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.059 · Cited by 1
Apoptosis in Neurodegenerative Diseases
Liang, Q., & Zhang, J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-381-7_21 · Cited by 1
Potential Therapies for Mitochondrial Dysfunction
Henchcliffe, C., & Beal, M. F. (2011) · Springer eBooks · doi:10.1007/978-0-85729-701-3_13 · Cited by 1
Huntington Disease and Other Genetic Choreas
Ha, A. D., & Jankovic, J. J. (2011) · Wiley eBooks · doi:10.1002/9781444346183.ch10 · Cited by 1
Chapter 11 Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
(2003) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70112-6 · Cited by 1
Identifying new therapeutics for Huntington's disease
Schilling, G., & Borchelt, D. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00060-4 · Cited by 1
Evidence from biomarkers and surrogate endpoints
Feigin, A. (2004) · Neurotherapeutics · doi:10.1007/bf03206617 · Cited by 1
Movement disorders
Marshall, F. J. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2261-9.50033-1 · Cited by 1
Huntington's Disease
Koroshetz, W. J. (2003) · Elsevier eBooks · doi:10.1016/b0-44-306557-8/50128-3
Prospects for Slowing the Progression of Parkinson's Disease
MAREK, K. L. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50009-6
Anti-Excitotoxic Therapies in Neurologic Diseases: Current Evidences and New Perspectives
Brighina, L., Aliprandi, A., Beretta, S., & Ferrarese, C. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8959-8_19
Disorders of the mitochondrial respiratory chain
Schapira, A. H. V. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.063
Embryonic stem cell models of CAG repeat disease
Lorincz, M. (2005) · The Cerebellum · doi:10.1080/14734220510007941
Murine Models of Huntington Disease
Sturrock, A., & Leavitt, B. R. (2009) · Future Neurology · doi:10.2217/fnl.09.34
Coenzyme Q10 and Behavior in Huntington’s Disease
Hickey, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00091-4
Pharmacological Strategies for Neurodegeneration and Overview of Clinical Trials
Ley, L., & Herdegen, T. (2004) · Springer eBooks · doi:10.1007/1-4020-2541-6_39
Neuroprotection in Huntington’s Disease
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_9
Huntington’s Disease
Raymond, L. A., & Leavitt, B. R. (2005) · Neurological disease and therapy · doi:10.1201/9780849358364.ch16
Clinical and Pathological Characteristics of Huntington Disease
Rao, J. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50026-8
Coenzym Q10 ohne neuroprotektiven Effekt
Carsten Saft, C. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2107-3
Coenzyme Q10 deficiency in elderly: Can nutritional supplementation play a role? Mini review
Am, C., Teresa, M., Pumpo, M. D., Giovanni, M., & Benvenuto, A. (2018) · The European Research Journal · doi:10.18621/eurj.411682 · Cited by 1

Authors: The Huntington Study Group
Corresponding author: The Huntington Study Group
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-08-14
Volume: 57
Issue: 3
Pages: 397-404
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.57.3.397
OpenAlex: W4245847463
Cited by: 312
References: 19
Citations by year: 2026: 2 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 3 · 2014: 9 · 2013: 5 · 2012: 16
FWCI: 7.24
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (NS R01-35284, R01NS035284)
National Center for Research Resources (RR-00044, RR 01066, RR 07122, M01RR001066, M01RR000044, RR00042, RR 00645, M01RR000042, M01RR000645)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords: Huntington's disease, coenzyme Q10, remacemide, functional decline, total functional capacity, disease-modifying therapy, early-stage Huntington's disease, adverse events, nausea and vomiting
MeSH terms: Acetamides, Adult, Coenzymes, Double-Blind Method, Female, Humans, Huntington Disease, Male, Middle Aged, Prognosis, Time Factors, Ubiquinone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks